Transgenic Rabbit Models in Proarrhythmia Research.

Area of Science:

• Cardiovascular Pharmacology
• Cardiac Electrophysiology
• Drug Safety Assessment

Background:

• Drug-induced proarrhythmia, often linked to QT interval prolongation, is a dangerous side effect.
• Current drug screening models typically use healthy subjects, failing to account for impaired repolarization reserve.
• Predicting proarrhythmia risk remains a significant challenge in drug development.

Purpose of the Study:

• To review the utility of transgenic long QT syndrome (LQTS) rabbit models for predicting drug-induced proarrhythmia.
• To summarize the electrophysiological properties and pharmacological studies of existing LQTS rabbit models.
• To highlight the advantages and limitations of LQTS models in proarrhythmia research.

Main Methods:

• Review of electrophysiological characteristics of transgenic LQTS rabbit models.
• Analysis of pharmacological proof-of-principle studies using these models.
• Comparison of different LQTS models with varying degrees of repolarization reserve impairment.

Main Results:

• Transgenic LQTS rabbit models exhibit distinct electrophysiological profiles reflecting impaired repolarization.
• Pharmacological studies demonstrate the potential of these models to identify proarrhythmic drug effects.
• Different LQTS models may be suitable for assessing drugs affecting specific cardiac ion channels.

Conclusions:

• Transgenic LQTS rabbit models represent a valuable tool for improving the prediction of drug-induced proarrhythmia.
• These models offer a more relevant platform for safety screening, especially in the context of compromised repolarization.
• Future research should focus on refining these models and exploring novel approaches for proarrhythmia risk assessment.